Global Intravenous Immunoglobulin (IVIG) Market Industry Analysis,Trends, and Forecast 2016 - 2024

Market Research Reports Search Engine (MRRSE) has recently added the report, titled, “Intravenous Immunoglobulin (IVIG) Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016-2024” to its offering.

The report reveals key trends, opportunities, drivers, and challenges prevailing in the global market for intravenous immunoglobulin (IVIG). Recently, there has been a greater preference for subcutaneous infusion of immunoglobulin than for intravenous infusion. Another major trend that is observed in the global intravenous immunoglobulin market is the rising demand originating from home care end users.

Request Sample Report : http://www.mrrse.com/sample/2162

The incidence of autoimmune disorders such as Kawasaki syndrome, multiple sclerosis, and primary humoral immunodeficiency (PIDD), in addition to neurological disorders, diabetes, and cancer has been increasing at an alarming rate. This is expected to boost demand for intravenous immunoglobulin worldwide. Some other key growth drivers in the global intravenous immunoglobulin market are a growing geriatric population and increasing usage in off-label indications.

On the contrary, chronic side effects such as muscle cramps and nausea caused by intravenous immunoglobulin and high costs of treatment will restrict market growth. Introduction of new payment and supporting models in order to cut down costs, however, will present substantial opportunities in the near future.

The chronic inflammatory demyelinating polyneuropathy (CDIP) has emerged as the leading segment by indication, in terms of revenue generation. In 2015, this segment was pegged at US$2,296.6 mn. Growing at a favorable CAGR of 9.2% during the forecast period 2016-2024 the CDIP segment is projected to achieve a value of US$4,989.4 mn by the end of 2024. Analysts predict that this segment will retain its dominant position over the next few years.

Based on geography, the market for intravenous immunoglobulin has been categorized into regions such as Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific. These regions have been further segmented to include countries such as France, Canada, Australia, Spain, the U.S., Italy, the U.K., Germany, China, India, Brazil, Japan, Mexico, Saudi Arabia and South Africa. North America leads the global market, with the U.S at the forefront, because of a high patient population and the consequent growing demand from hospitals.

The global intravenous immunoglobulin (IVIG) market appears to be highly consolidated as the top four players, CSL Behring LLC, Grifols S.A., Baxalta Incorporated, and Octapharma AG held a whopping 70.0% share in 2015. Because of its phenomenal geographic penetration, Grifols S.A. held a share of 23.0%, closely followed by CSL Behring LLC, who accounted for a share of 21.5% in the same year.

Some of the major companies operating in the global market for intravenous immunoglobulin discussed in the report are LFB Biomedicaments S.A., CSL Behring LLC, Biotest AG, Octapharma AG, Baxalta Incorporated, Kedrion S.p.A., Sanquin Plasma Products B.V., and China Biologic Products, Inc. Shire plc has announced merger with Baxalta Incorporated in June 2016, marking its entry into the global intravenous immunoglobulin (IVIG) market.

Browse Full Report with TOC:http://www.mrrse.com/intravenous-immunoglobulin-market

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-730-0559
Email: sales@mrrse.com
Google+: https://plus.google.com/u/0/109558601025749677847/posts
Linked in: https://www.linkedin.com/company/mrrse
Twitter: https://twitter.com/MRRSEmrrse

This release was published on openPR.